Financial Data and Key Metrics Changes - Bausch Health reported a revenue of $2,796 million for Q4 2025, reflecting a 9% increase year-over-year on a reported basis [11] - Adjusted EBITDA for Q4 was $1,052 million, marking a 13% increase compared to the same quarter last year [11] - For the full year 2025, revenue grew by 7% on a reported basis and 6% on an organic basis [8] Business Line Data and Key Metrics Changes - Salix revenues in Q4 were $693 million, a 9% increase year-over-year [14] - Solta Medical segment revenues were $137 million, a slight decrease of 1% on a reported basis [16] - Diversified segment revenues increased by 12% to $255 million, primarily due to improved net pricing [17] Market Data and Key Metrics Changes - International segment revenues were $306 million, a 10% increase on a reported basis [15] - EMEA and LatAm markets showed double-digit growth, while Canada experienced a 6% contraction [15] - South Korea's revenue for Solta was up 40%, making it the largest revenue-generating geography for Solta in 2025 [16] Company Strategy and Development Direction - The company aims to enhance its operational assets through innovation and optimizing brand growth globally [23] - Bausch Health is focused on business development opportunities to expand its portfolio and maximize shareholder value [23] - The acquisition of Shibo's aesthetics business in China is expected to strengthen the company's market presence [8][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong performance across markets and improved capital structure [6][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance of $5.25 billion to $5.4 billion [21][22] - Management acknowledged the disappointment regarding the RED-C trial results but remains committed to exploring new development opportunities [10] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow and reduced net debt by approximately $320 million in Q4 [13][8] - A significant debt exchange improved the company's debt maturity profile by approximately $1.7 billion [8] Q&A Session Summary Question: What is the updated decision framework for the separation post RED-C readout? - Management stated there is no change in focus on debt repayment and reinvestment in the business despite disappointment in RED-C results [34] Question: Can you provide more details about business development plans? - Management is screening assets for potential acquisitions and leveraging their commercial team for growth opportunities [37][38] Question: What is the impact of higher-than-planned residual volume from Medicaid? - Most of the residual volume was associated with XIFAXAN, amounting to less than $50 million in revenue for Q4 [80] Question: What are the key events to watch regarding Xifaxan generics? - Management confirmed that a generic is expected in January 2028, with ongoing legal proceedings affecting exclusivity [86] Question: What is the expected EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would be around $2.7 billion, reflecting a dip compared to 2025 [88]

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025, reaching $2,796 million compared to the same quarter in 2024 [11] - Adjusted EBITDA for Q4 was $1,052 million, reflecting a 13% year-over-year increase [11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA increased by 10% [19] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year [14] - Solta Medical segment revenues were $137 million, a slight decrease of 1% year-over-year, impacted by distributor transition [16] - Diversified segment revenues increased by 12% to $255 million, primarily due to improved net pricing [17] Market Data and Key Metrics Changes - International segment revenues were $306 million, a 10% increase on a reported basis, with mixed results across geographies [15] - EMEA and Latin America showed double-digit growth, while Canada contracted by 6% due to increased generic competition [15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally [23] - Bausch Health is focused on business development opportunities to expand its portfolio and maximize shareholder value [23] - The acquisition of XiBo strengthens the company's presence in the Chinese aesthetics market, a key growth area [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong performance across markets and improved capital structure [6][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance of $5.25 billion to $5.4 billion [21][22] - Management acknowledged the disappointment regarding the RED-C trial results but emphasized ongoing focus on debt repayment and business reinvestment [34] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [8][14] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange [8] Q&A Session Summary Question: What is the updated decision framework for the separation post RED-C readout? - Management stated there is no change in focus, continuing to prioritize debt repayment and business reinvestment [34] Question: Can you provide more details about business development plans? - Management is screening assets for potential acquisitions, leveraging their strong commercial team [37] Question: What are the expected impacts of the Shibo integration on revenue and EBITDA growth? - The integration is progressing smoothly, with some accounting impacts expected in Q4 [44][46] Question: What is the outlook for Xifaxan generics and exclusivity? - Management is focused on maximizing Xifaxan's value and is monitoring ongoing legal proceedings regarding generics [86] Question: How will EBITDA shape up in 2027 relative to 2025? - Management reiterated that 2026 and 2027 EBITDA would be similar to 2025, with expected growth platforms to offset declines [66]

Financial Data and Key Metrics Changes - Bausch Health reported a revenue increase of 9% in Q4 2025 compared to Q4 2024, reaching $2,796 million, with adjusted EBITDA rising by 13% to $1,052 million [10][11] - For the full year 2025, revenue grew by 7% and adjusted EBITDA by 10%, indicating strong operational performance [18][19] - Adjusted gross margin was 71.6%, down 80 basis points year-over-year, while adjusted operating expenses increased by $75 million to $1,033 million [10][11] Business Line Data and Key Metrics Changes - Salix revenue in Q4 was $693 million, a 9% increase year-over-year, driven by strong demand and promotional efforts [12] - Solta Medical segment revenues decreased by 1% to $137 million, impacted by distributor transition in China, but would have shown mid-single-digit growth without this effect [15][16] - The diversified segment saw a 12% revenue increase to $255 million, primarily due to improved net pricing [16] Market Data and Key Metrics Changes - International segment revenues were $306 million, up 10% on a reported basis, with EMEA and LatAm showing double-digit growth, while Canada contracted by 6% [13][14] - The Latin American market returned to growth with a 22% revenue increase, while Canada faced challenges due to increased generic competition [14][15] Company Strategy and Development Direction - The company aims to enhance operational assets through innovation and optimize brand growth globally, with a focus on business development opportunities [21][22] - The acquisition of Shibo's aesthetics distribution platform in China is expected to strengthen the company's market presence and enhance direct engagement with providers [7][26] - Strategic priorities for 2026 include maximizing shareholder value and optimizing the capital structure following significant refinancing [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong cash generation and improved capital structure, allowing for proactive business development [5][7] - The company anticipates a stronger growth rate in the first half of 2026, with a revenue guidance range of $5.25 billion to $5.4 billion [20][21] - Management acknowledged the disappointment regarding the RED-C trial results but remains focused on advancing other development opportunities [9] Other Important Information - The company achieved over $1 billion in adjusted operating cash flow for the year and reduced net debt by approximately $320 million in Q4 [7][12] - The debt maturity profile was improved by approximately $1.7 billion through a debt exchange, providing additional flexibility for future opportunities [7][19] Q&A Session Summary Question: Post RED-C readout, what is the updated decision framework for separation and debt repayments? - Management stated there is no change in focus, continuing to prioritize debt repayment and reinvestment in the business [33] Question: Can you provide more details about business development plans? - Management is screening various assets for potential acquisitions, leveraging their strong commercial team [36][37] Question: What is the impact of the Shibo integration on revenue and EBITDA growth? - The integration is progressing well, with a minor EBITDA impact of $10-$15 million due to accounting adjustments [45][47] Question: What are the expectations for Xifaxan generics? - Management confirmed that a generic is expected by January 1, 2028, and is focused on maximizing current value [84] Question: What is the EBITDA trajectory for 2027? - Management indicated that 2027 EBITDA would likely be around $2.7 billion, reflecting a dip compared to 2025 [86]

Company Overview - InMode Ltd. is an Israeli-based company specializing in medical aesthetics, providing platforms and technology for both minimally invasive and non-invasive procedures [1] - The company offers 12 platforms that deliver a variety of treatments, including radio-frequency (RF) micro-needling [1] Investment Philosophy - The investment approach emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve wealth creation [1] - The strategy includes a mix of steady accumulation of high-quality assets along with high-risk/high-reward opportunities and transformative technologies [1] Academic Background - The individual associated with the analysis has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University [1]

Core Insights - Sisram Medical Ltd, through its subsidiary Alma, showcased advancements in Intelligent Aesthetics at the IMCAS World Congress, emphasizing a technology-driven approach to aesthetic treatments [1] - The company presented new clinical data and case studies that reinforce its leadership in energy-based aesthetic solutions, particularly in scar management, rejuvenation, and tattoo removal [1] Group 1: Company Developments - Alma highlighted its innovative multi-technology laser platforms for various applications, including advanced laser-based rejuvenation and complex tattoo removal [1] - The Alma Hybrid platform was featured for its effectiveness in managing keloid scars in conjunction with surgery and steroid delivery [1] - The company’s advanced skin analysis platform, Alma IQ, supports personalized assessments and treatment planning from the initial patient interaction [1] Group 2: Industry Impact - The IMCAS World Congress serves as a significant platform for discussing the future of medical aesthetics, with Sisram's participation underscoring its commitment to evidence-based practices and technological innovation [1] - Discussions at the congress included the role of intelligent technologies and clinical insights in shaping the future landscape of medical aesthetics, attended by industry leaders [1]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns including hyperpigmentation and premature aging [6] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi's saypha MagIQ™ across Alpha's network, aiming to generate real-world evidence of the product's integration into clinical environments [2][3] - The program will collect standardized data to evaluate clinical performance and patient experience, with initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi's saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi saypha MagIQ™ across Alpha's network, focusing on generating real-world evidence of the product's integration into clinical environments [2][3] - The program aims to assess both clinical performance and patient experience, with standardized data collection across participating practices, and initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi saypha ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]

Core Insights - A foreign investment fund is considering acquiring InMode, a medical aesthetics company, for $1.1 billion, leading to a surge in InMode's stock price [1] Company Summary - InMode is positioned in the medical aesthetics sector, which is experiencing increased interest from foreign investment [1] Industry Summary - The medical aesthetics industry is attracting significant investment, as evidenced by the potential acquisition of InMode for $1.1 billion [1]

Sheffield, United Kingdom--(Newsfile Corp. - January 25, 2026) - Este Medical Group has announced the opening of a new clinic in Sheffield, marking the company's 25th clinic worldwide and further expanding its footprint across the United Kingdom. The new location reflects the group's continued growth and long-term investment in accessible medical and aesthetic care.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/9032/281523_6a2e12669453d817_001full.jpgLocated ...

Pensacola, Florida--(Newsfile Corp. - January 22, 2026) - Grace + Grey Med Spa is proud to announce that Aesthetic Injector Liz deChadenedes has been selected as one of the Top 100 Best Aesthetic Providers in America for 2026, a prestigious national honor recognizing excellence in the field of medical aesthetics, by Best Aesthetic Injectors. The Top 100 Best Aesthetic Providers in America distinction is awarded annually and is determined through a combination of peer nominations and patient votes, highl ...